NFATC2 and bladder transitional cell carcinoma: In the combined TCGA dataset as well as in both datasets demonstrating poor progression-free and overall survival in NFATc2-High expressers, BLCA and LGG, NFATc2-High tumors were more likely to be considered high-grade (BLCA: 98.0% vs. 88.2%, p = 0.002; LGG: 64.3% vs. 45.7%, p = 0.003; All TCGA: 21.9% vs. 20.7%, p = 0.05; Fig. 4i).